Kamari Pharma Raises $8 Million from the Sino-Israeli GIBF2 Fund
Summary
Kamari, Founded by Pontifax and Arkin Bioholdings, is a clinical stage company developing proprietary drugs for complex dermatological diseasesREHOVOT, Israel and GUANGZHOU, China, Sept. 19, 2022 /PRNewswire/ -- Kamari Pharma announced today the completion of an $8 million investment by the Chinese fund GIBF2, managed by Dr. Shuki Gleitman, Prof. Shlomo Noy, Mr. Avner Lushi and Mr. Carl Geng.Kamari was established at the end of 2018 by the leading Israeli based biotechnology funds Pontifax and Arkin Bioholdings. These innovative drugs are intended for the treatment of various dermatological diseases, such as keratoderma, Lichen Simplex Chronicus and other severe genetic skin disorders. The Chairman of Kamari is Prof. David Aviezer, previously CEO of Protalix Biotherapeutics, who led it to its first FDA approval and listing on the New York Stock Exchange. Kamari is led by an experienced and professional management team, which includes Dr. Liora Braiman, CSO, and Asaf Yarkoni, CFO. Our mutual goal is to develop innovative activity in China and to build value in this major market, which foreign companies typically leave in the hands of local partners."Prof.
Funding
Review available funding amount, funding date, investors, and linked company information related to Kamari Pharma Raises $8 Million from the Sino-Israeli GIBF2 Fund in the interactive ISVWorld profile.